Impact of GP IIIa Gene Polymorphism on Heart Stenting Outcomes
Author Information
Author(s): Claire Le Hello, Rémy Morello, Agnès Lequerrec, Christine Duarte, John Riddell, Martial Hamon
Primary Institution: Caen Universitary Hospital
Hypothesis
Does the GP IIIa PlA1/A2 polymorphism affect long-term outcomes in patients with coronary artery disease after stenting?
Conclusion
The GP IIIa PlA1/A2 polymorphism does not influence the long-term clinical outcome in patients with symptomatic coronary disease undergoing percutaneous coronary intervention with stent implantation.
Supporting Evidence
- The study involved 1,111 patients, but only 963 were included in the final analysis.
- The incidence of major adverse cardiac events was similar across different genotype groups.
- Independent risk factors for adverse outcomes included low left ventricular ejection fraction and lack of certain medications.
Takeaway
This study looked at whether a specific gene change affects heart health after stenting. It found that this gene change doesn't really make a difference.
Methodology
A prospective observational study involving genotyping of 1,111 Caucasian patients treated with coronary stenting, with follow-up for major adverse cardiac events.
Potential Biases
Potential bias due to the study being conducted in a single center and the small sample size of certain genotypes.
Limitations
The study was conducted in a single hospital, had a small number of A2/A2 patients, and a significant number of patients were lost to follow-up.
Participant Demographics
The study included 963 Caucasian patients, with 80.9% males and a mean age of 64.4 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website